Qi-Xing Tan1, Qing-Hong Qin1, Wei-Ping Yang2, Bin Lian1, Chang-Yuan Wei1. 1. Department of Breast Surgery, Guangxi Medical University Tumor Hospital Nanning, China. 2. Department of Ultrasound Diagnosis, Guangxi Medical University Tumor Hospital Nanning, China.
Abstract
BACKGROUND: To investigate the prognostic value of hormone receptor (HR) status conversion after neoadjuvant chemotherapy (NAC) in patients with primary breast cancer. METHODS: 267 stage II-III breast cancer patients treated with NAC who had residual disease in the breast after NAC were retrospectively studied. The patients were divided into four groups based on the HR status: Group A, patients with HR-positive both before and after NAC; Group B, patients with HR status positive-to-negative change; Group C, patients with HR status negative-to-positive change; Group D, patients with HR-negative both before and after NAC. Patients with positive HR status (regardless of before or after NAC) were treated with adjuvant endocrine therapy, and a survival analysis was performed. RESULTS: In total, 15.7% of patients had HR status change after NAC. progression-free survival (PFS) in Group A was similar to that in Group C (hazard ratio, 1.16; P = 0.652), but that in Group B was significantly lesser than that in Group A (hazard ratio, 6.88; P = 0.001), and that in Group C was significantly longer than that in Group D (hazard ratio, 6.88; P = 0.001). A similar pattern of results was obtained for overall survival (OS). CONCLUSIONS: The switch of HR status after NAC is remarkable for breast cancer. An HR switch may identify patients who would benefit from adjuvant endocrine therapy and impact the long-term outcome.
BACKGROUND: To investigate the prognostic value of hormone receptor (HR) status conversion after neoadjuvant chemotherapy (NAC) in patients with primary breast cancer. METHODS: 267 stage II-III breast cancerpatients treated with NAC who had residual disease in the breast after NAC were retrospectively studied. The patients were divided into four groups based on the HR status: Group A, patients with HR-positive both before and after NAC; Group B, patients with HR status positive-to-negative change; Group C, patients with HR status negative-to-positive change; Group D, patients with HR-negative both before and after NAC. Patients with positive HR status (regardless of before or after NAC) were treated with adjuvant endocrine therapy, and a survival analysis was performed. RESULTS: In total, 15.7% of patients had HR status change after NAC. progression-free survival (PFS) in Group A was similar to that in Group C (hazard ratio, 1.16; P = 0.652), but that in Group B was significantly lesser than that in Group A (hazard ratio, 6.88; P = 0.001), and that in Group C was significantly longer than that in Group D (hazard ratio, 6.88; P = 0.001). A similar pattern of results was obtained for overall survival (OS). CONCLUSIONS: The switch of HR status after NAC is remarkable for breast cancer. An HR switch may identify patients who would benefit from adjuvant endocrine therapy and impact the long-term outcome.
Entities:
Keywords:
Breast cancer; changes; hormone receptor; neoadjuvant chemotherapy
Authors: Marco Colleoni; Giuseppe Viale; David Zahrieh; Giancarlo Pruneri; Oreste Gentilini; Paolo Veronesi; Richard D Gelber; Giuseppe Curigliano; Rosalba Torrisi; Alberto Luini; Mattia Intra; Viviana Galimberti; Giuseppe Renne; Franco Nolè; Giulia Peruzzotti; Aron Goldhirsch Journal: Clin Cancer Res Date: 2004-10-01 Impact factor: 12.531
Authors: S Taucher; M Rudas; M Gnant; K Thomanek; P Dubsky; S Roka; T Bachleitner; D Kandioler; C Wenzel; G Steger; M Mittlböck; R Jakesz Journal: Endocr Relat Cancer Date: 2003-03 Impact factor: 5.678
Authors: Priya Rastogi; Stewart J Anderson; Harry D Bear; Charles E Geyer; Morton S Kahlenberg; André Robidoux; Richard G Margolese; James L Hoehn; Victor G Vogel; Shaker R Dakhil; Deimante Tamkus; Karen M King; Eduardo R Pajon; Mary Johanna Wright; Jean Robert; Soonmyung Paik; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544
Authors: R J Burcombe; A Makris; P I Richman; F M Daley; S Noble; M Pittam; D Wright; S A Allen; J Dove; G D Wilson Journal: Br J Cancer Date: 2005-01-17 Impact factor: 7.640
Authors: Srivarshini Cherukupalli Mohan; Sarah Walcott-Sapp; Minna K Lee; Marissa K Srour; Sungjin Kim; Farin F Amersi; Armando E Giuliano; Alice P Chung Journal: Ann Surg Oncol Date: 2021-03-21 Impact factor: 5.344